banner

Posts tagged as: Generx back to homepage

Cardium Wins Patent Rights to Heart Disease Treatment, Settles Dispute with Boston Scientific Cardium Wins Patent Rights to Heart Disease Treatment, Settles Dispute with Boston Scientific(0)

Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease

Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascular Gene Therapy in the U.S. and Europe

Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy Read More

EC Approval of Glybera A Significant Industry Milestone in Gene Therapy EC Approval of Glybera A Significant Industry Milestone in Gene Therapy(0)

Commenting on the October 25 approval by the European Commission for its gene therapy, Glybera®, Dutch biotech company uniQure said Monday it plans to start selling Glybera in Europe by mid-2013 and predicted a boom of similar therapies.  The EC approval marks Glybera as the first gene therapy to be approved in the Western world. Read More

Excellagen Presentation on Cardium Therapeutics Website Excellagen Presentation on Cardium Therapeutics Website(0)

An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website.  The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations. Read More

Cardium to Present at Rodman and Renshaw Conference Cardium to Present at Rodman and Renshaw Conference(0)

Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference

Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at Read More

Cardium and Generx Featured on San Diego Biotechnology Connection Cardium and Generx Featured on San Diego Biotechnology Connection(0)

An article this morning on San Diego Biotechnology Connection website, discusses an important breakthrough in technology and regenerative medicine.  The article provides details of Cardium Therapeutics (NYSE MKT: CXM) and its Generx product candidate, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease.  The article titled, “Cardium Therapeutics reports advance – gene therapy process technology” was written by Rex Graham, a science journalist with a master’s degree in microbiology and a 30-year career Read More

Cardium Therapeutics Excellagen Named as Top Ten Innovation in Podiatry Cardium Therapeutics Excellagen Named as Top Ten Innovation in Podiatry(0)

Last year, industry specialist GlobalData released a report estimating the global diabetic foot ulcer therapeutics market to be valued at $1.15 billion in 2010 with expectations of growth to $2.28 billion by 2017.  A recent article by BBC News called today’s diabetic foot care “appalling” and leading to “an increased risk of having a foot amputated.”  With their Excellagen product, Cardium Therapeutics (NYSE MKT: CXM), a company in the same industry as Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), Read More

Cardium Therapeutics in the News Cardium Therapeutics in the News(0)

It’s been a busy several weeks for Cardium Therapeutics (NYSE MKT: CXM) as industry attention and investor buzz continues to build around regenerative medicine companies. Generx®, Cardium’s flagship gene therapy product candidate, is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. In March 2012, Cardium initiated its Phase 3 registration clinical trial in Russia which is expected to enroll approximately 100 patients at up to eight leading cardiovascular centers. The San Diego Biotechnology Read More

Cardium CEO Discusses Generx, Excellagen and MedPodium with CEOCFOInterviews.com Cardium CEO Discusses Generx, Excellagen and MedPodium with CEOCFOInterviews.com(0)

In their latest interview, www.ceocfointerviews.com spent some time with Cardium Therapeutics (NYSE MKT: CXM) CEO and Chairman Christopher J. Reinhard.  The article title, “With their Regenerative Medicine Product Generx® for Coronary Artery Disease in Phase 3 Registration Study for International Markets, Cardium Therapeutics Inc. is Leading the Evolution of a Revolution” can be seen on the CEO/CFO Interviews website at: Read More

Cardium Therapeutics Presents at Marcum MicroCap Conference 2012 Video Cardium Therapeutics Presents at Marcum MicroCap Conference 2012 Video(0)

Christopher J. Reinhard, Chairman & CEO presented at the Marcum MicroCap Conference on June 20, 2012 at at the Roosevelt Hotel in New York City. In the presentation, Mr. Reinhard details Cardium products, including Generx as a product candidate for advanced coronary artery disease, Excellagen for wound care management and the company’s line of MedPodium neutraceuticals,metabolics and aesthetics. Read More

Cardium Therapeutics Investor Presentation June 2012 Cardium Therapeutics Investor Presentation June 2012(0)

Cardium Therapeuitcs (NYSE MKT: CXM) is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to partnering, commercialization and other economic monetizations. Cardium’s investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing and cardiovascular Read More



Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.